Short Interest in Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY) Decreases By 67.7%

Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY) was the target of a large decline in short interest during the month of March. As of March 15th, there was short interest totalling 3,200 shares, a decline of 67.7% from the February 28th total of 9,900 shares. Based on an average daily volume of 3,300 shares, the short-interest ratio is presently 1.0 days.

Clinuvel Pharmaceuticals Stock Down 4.6 %

OTCMKTS:CLVLY traded down $0.35 during trading hours on Friday, hitting $7.28. The company had a trading volume of 454 shares, compared to its average volume of 2,263. The company has a 50-day moving average of $7.44 and a 200 day moving average of $8.30. Clinuvel Pharmaceuticals has a 1 year low of $6.80 and a 1 year high of $11.40.

About Clinuvel Pharmaceuticals

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).